The Sai Life Sciences IPO is set to raise Rs 3,042.62 crores, consisting of a fresh issue of 1.73 crore shares worth Rs 950 crore and an offer for sale (OFS) of 3.81 crore shares, valued at Rs 2,092.62 crores. This IPO will open for subscription from December 11, 2024, to December 13, 2024. Allotments are expected to be finalized by December 16, 2024, with the listing on BSE and NSE scheduled for December 18, 2024.
The IPO offers a price band of ₹522 to ₹549 per share, making it accessible for a wide range of investors. The minimum lot size for retail investors is 27 shares, requiring an investment of ₹14,823. Qualified Institutional Buyers (QIB) can bid for a minimum of 14 lots (378 shares), amounting to ₹207,522, while High Net-Worth Individuals (HNIs) need to apply for 68 lots (1,836 shares), with an investment of ₹1,007,964.
With an estimated market capitalization of Rs 11,400 crore post-listing, the Sai Life Sciences IPO presents an exciting opportunity for investors seeking exposure to the growing pharmaceutical sector. The fresh issue will help the company strengthen its position in the industry, while the OFS will provide liquidity to the selling shareholders. Don’t miss this chance to invest in a company with a promising future.
Overview of Contents
About Sai Life Sciences Company
Sai Life Sciences Limited is a leading Contract Research, Development, and Manufacturing Organization (CRDMO), established in January 1999. The company specializes in researching, developing, and manufacturing small-molecule new chemical entities (NCEs). Sai Life Sciences provides comprehensive and tailor-made services to biotech firms and global pharmaceutical companies, helping them advance their drug discovery, development, and manufacturing processes.
With over 280 innovator pharmaceutical clients—including 18 of the top 25 pharmaceutical companies globally based on revenue (as of 2023)—Sai Life Sciences has built a reputation for excellence in the pharmaceutical and biotech sectors. The company operates across multiple regions, including the US, UK, Europe, and Japan, offering its clients a global reach and extensive expertise.
As of September 30, 2024, Sai Life Sciences employed 3,135 professionals, including 2,353 scientific staff. The team consists of highly qualified experts, with 302 Ph.D.s and 1,475 master’s degrees. This scientific expertise enables the company to offer a full range of services, from chemistry, manufacturing, and control (CMC) to contract development and manufacturing (CDMO).
The company’s CRO services are integrated, covering areas like biology, chemistry, and drug metabolism. Sai Life Sciences is committed to delivering high-quality, cost-effective, and responsive solutions, focusing on helping its clients navigate the complexities of the pharmaceutical industry. This adaptability and continuous innovation have driven Sai Life Sciences’ growth, outperforming competitors with a strong revenue and EBITDA CAGR from 2022 to 2024.
Looking ahead, Sai Life Sciences aims to develop innovative treatments for currently incurable conditions, striving to make a significant impact on the future of healthcare. Their integrated CRDMO platform, commitment to quality, and deep scientific expertise continue to make them a trusted partner in the global pharmaceutical industry.